Reckitt Benckiser Group plc (OTCMKTS:RBGLY) Short Interest Update

Reckitt Benckiser Group plc (OTCMKTS:RBGLY) was the target of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 50,500 shares, a decline of 51.1% from the February 28th total of 103,300 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 609,700 shares, the short-interest ratio is presently 0.1 days.

Reckitt Benckiser Group Price Performance

Shares of OTCMKTS:RBGLY traded up $0.20 during trading on Friday, reaching $13.56. The stock had a trading volume of 183,173 shares, compared to its average volume of 336,059. The company has a debt-to-equity ratio of 0.97, a quick ratio of 0.47 and a current ratio of 0.69. Reckitt Benckiser Group has a 52 week low of $10.24 and a 52 week high of $14.10. The business’s 50-day moving average price is $13.23 and its 200 day moving average price is $12.58.

Reckitt Benckiser Group Increases Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 11th will be given a $0.2909 dividend. This is a positive change from Reckitt Benckiser Group’s previous dividend of $0.19. The ex-dividend date is Friday, April 11th.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on RBGLY. Hsbc Global Res raised Reckitt Benckiser Group from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 11th. Royal Bank of Canada reissued an “outperform” rating on shares of Reckitt Benckiser Group in a research report on Friday, March 7th. Barclays downgraded Reckitt Benckiser Group from an “overweight” rating to an “equal weight” rating in a report on Tuesday, February 4th. Finally, HSBC raised Reckitt Benckiser Group from a “hold” rating to a “buy” rating in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Reckitt Benckiser Group presently has a consensus rating of “Buy”.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.